Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study.
Borja QuirogaMaria José SolerAlberto Ortiz ArduanCarlos Jesús Jaravaca MantecónNathasha Nava PérezMarta Serra MartínYurika SatoAntonio José Marin FrancoDiana Flor Pazmiño ZambranoRafael Lucena ValverdeMayra Ortega DiazCarmen Calderón GonzálezJuan Manuel Cazorla LópezMónica PereiraEmilio González ParraAna Sánchez HorrilloCarmen Sánchez GonzálezNestor G ToapantaSecundino CigarránRosa Sánchez HernándezSoledad Pizarro SánchezMaría Muñiz RincónNuria Garcia-FernándezNatalia Blanco CastroRocío Collantes MateoManuel Augusto Quiroz MoralesBeatriz Escamilla-CabreraIsabel Berdud GodoyBeatriz Gil-Casares CasanovaAlba LeyvaJosé RojasRon T GansevoortPatricia de Sequeranull nullPublished in: Clinical kidney journal (2022)
In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.